Flotillin2 Expression Correlates with HER2 Levels and Poor Prognosis in Gastric Cancer

Zhi Zhu1, Jinou Wang2, Zhe Sun1, Xuren Sun3, Zhenning Wang1, Huimian Xu1*

Abstract

Objective: Flotillin gene is known as a tumor promoter or suppressor, depending on the tumor type or tumor stage. We aimed to investigate the clinical significance of flotillin2 protein expression in gastric cancer.

Methods: We examined flotillin2 and erbB2 levels in tissue microarray of 282 gastric cancer samples and analyzed the association between flotillin2 levels, clinicopathologic factors and prognosis. The regulation of erbB2 by flotillin2 was examined with flotillin2 siRNA–transfected gastric cancer cells.

Results: Flotillin2 partially co-localized with erbB2 at the plasma membrane as detected by confocal microscopy, levels of erbB2 were reduced after flotillin knockdown in SGC-7901 cancer cells, and the expression of flotillin2 was positively correlated with that of erbB2. In non-neoplastic gastric mucosa, flotillin2 was not expressed in the epithelial compartment. In gastric cancer, positive staining of flotillin2 was shown in 129 (45.7%) of 282 cases, also, it was significantly associated with a Lauren grade, histologic type, lymphovascular invasion and tumor location. Moreover, survival analysis showed that flotillin2 expression was an independent prognostic factor of poor survival (p<0.001).

Conclusions: These results indicate that a positive correlation exists between flotillin2 and erbB2 expression levels, flotillin2 maybe involved in the stabilization of erbB2 at the plasma membrane, flotillin2 is significantly correlated with cancer progression and poor prognosis in gastric cancer.

Introduction

Many plasma membrane proteins are known to be involved in cell proliferation, cell adhesion, cell motility and tumor cell invasion, accounting for more than two thirds of currently known drug targets. The cell membrane and associated proteins are of substantial interest with regard to various aspects of tumor, from carcinogenic and metastatic mechanisms to molecular diagnosis and therapeutics [1]. Flotillins are associated with vesicular invaginations of the plasma membrane, and act as regulators of signal transduction [2]. Among flotillin family members, there are two different flotillin genes (flotillin1 and 2), flotillin2 protein expression has been reported in some human cancer cell lines and tumor samples [3,4,5,6]. Since flotillin2 directly interacts with signaling molecules such as receptors, kinases, adhesion molecules and G proteins, it acts as a tumor modulator through the regulation of cell proliferation, differentiation, apoptosis, adhesion and invasion [4].

Overexpression of erbB2 (human epidermal growth factor receptor 2), also known as HER2, is membrane-associated tyrosine kinase that can lead to the activation of cellular signal transduction systems, resulting in the cellular transformation and cell prolifer-
Figure 1. Correlation between flotillin2 and erbB2 expression, flotillin2 co-localize with erbB2 at the plasma membrane. Representative protein expression of (A) flotillin2 and (B) erbB2 in a tissue microarray core was taken from a gastric carcinoma. SGC-7901 gastric cancer cells were stained with anti-erbB2, anti-flotillin2 antibody respectively, the stained antibody was visualized by TRITC/FITC-conjugated goat anti-mouse IgG antibody, and the slides were then examined by a confocal laser scanning microscope. TRITC (erbB2) is shown as red (C), FITC (flotillin2) as green (D), and the merge of green and red becomes yellow (E).
doi:10.1371/journal.pone.0062365.g001

Figure 2. Knockdown of flotillin-2 resulted in a stronger reduction of erbB2. Amplification of HER2 gene was determined by FISH. HER2 gene amplification in a cluster pattern (red) was observed in (A) MGC-803, (B) BGC-823 and (C) SGC-7901 gastric cancer cells, HER2 over expression in human SGC-7901 cell. (D) Western blot analysis and (E) Quantitative real-time PCR were accessed for erbB2 and flotillin2 in SGC-7901 cell line after knockdown of flotillin-2. The expression status of flotillin2 is highly concordant with that of erbB2, siRNA was blank vector, β-Actin was used as internal control.
doi:10.1371/journal.pone.0062365.g002
Table 1. Flotillin2 expression in relation to the status of erbB2 expression.

| Flotillin2 positive | Flotillin2 negative | p value |
|--------------------|---------------------|---------|
| Positive           | 43 (38.6%)          | 16 (61.4%) | <0.001* |
| Negative           | 86 (72.9%)          | 137 (27.1%) |

Figures in parentheses are percentages, % is within ErbB2
*p<0.05 considered to be statistically significant.
doi:10.1371/journal.pone.0062365.t001

Materials and Methods

Tissue Samples and Follow-Up

A total of 282 patients who had surgery for gastric cancer between January 2006 and December 2009 at the First affiliated hospital of China Medical University was selected for this study. All patients-derived specimens were collected and archived under protocols approved by the Institutional Review Boards of the First affiliated Hospital China Medical University. The diagnosis was confirmed by at least two pathologists and staging was based on pathological findings according to the 7th American Joint Committee on Cancer guidelines. The median duration of follow-up was 51 (range, 5–78) months.

The 282 patients who underwent gastrectomy were subjected to close clinical observation, including chest and abdominal CT imaging, CEA level, and blood testing at 2- to 3-month intervals and a yearly gastroscopy. Overall survival (OS) rates were defined as the interval from the initial surgery to clinically or radiologically proven recurrence or metastasis and death, respectively. The end date of the follow-up study for conducting the analysis was June 29, 2012.

Ethics statement

Ethical approval for this research was obtained from the Research Ethics Committee of China Medical University, China. All patients providing tumor tissue as well as normal gastric tissue samples signed a consent form prior to surgical removal of the gastric carcinoma to allow for this research to be undertaken.

TMA construction and immunohistochemistry

Hematoxylin and eosin (H&E)-stained slides were screened for optimal tumor tissue and noncancerous tissue adjacent to tumor (at least 2 cm from the tumor) and TMA slides were constructed with a tissue manual arraying instrument. Two cores were collected from each formalin-fixed, paraffin-embedded (FFPE) gastric cancer tissue sample and from each normal gastric mucosa sample using a 1.0-mm diameter punch instrument. Samples from the same patient were spotted next to each other to ensure similar reaction conditions for the normal and tumor tissue of that patient. Immunohistochemical Analysis was performed on FFPE samples as described previously using an Envision kit (Dako Cytomation, Glostrup, Denmark) [12]. Pressure cooker mediated antigen retrieval was performed in citrate buffer (pH 6.0) for 7 min. Sections were incubated with 1 200 dilution of anti-flotillin2 (Santa Cruz, sc-25307) and erbB2 (sc-33684) overnight at 4°C, and then incubated with goat anti-mouse or anti-rabbit Envision System Plus-HRP (Dako Cytomation) for 30 min at room temperature. After rinsing three times in PBS for 10 min each, the sections were incubated with DAB for 1 min, counterstained with Mayer hematoxylin, dehydrated, and mounted.

Evaluation of Immunohistochemical Staining

Immunoreactivity was evaluated independently by two researchers who were blinded to patient outcome. The evaluation was based on the staining intensity and extent of staining. Staining intensity for flotillin2 and erbB2 was scored as 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). Staining extent was scored as 0 (0%), 1 (1–25%), 2 (26–50%), 3 (51–75%), and 4 (76–100%), depending on the percentage of positive-stained cells. The sum of the staining intensity and the staining extent scores was used as the final staining score. The specimens were divided into three groups according to their overall scores: 0–1, negative, 2–4, weak positive, and 5–7, strong positive.

FISH analysis for gastric cancer cells

Amplification of the erbB2 gene was determined by dual-colour FISH method using the Passvision HER2 DNA probe Kit (Vysis Inc. Downers Grove, IL, USA) according to the manufacturer’s protocol. The HER2-Spectrum Orange probe contains a DNA sequence specific for the erbB2 human gene locus and hybridizes to region 17q11.2–q12 of human chromosome. The CEP 17 (chromosome enumeration probe 17) used as a control contains alpha-satellite DNA. The nucleus was counterstained with 40, 6-diamidino-2-phenylindole (DAPI). The nude mice of gastric cancer model (SGC-7901, MGC-803 and BGC-823) were made as described before [13,14]. The tumor slides were observed under BX50 fluorescence microscope equipped with digital camera (DP50) (Olympus, Tokyo, Japan), and the images were captured with Viewfinder software. A cell was considered to show amplification when a definite cluster or more than 10 signals for erbB2 was found.

Cell culture and transfections

Gastric cancer cell lines SGC-7901 (moderately differentiated), MGC-803 and BGC-823 (poorly differentiated) were all purchased from the cell bank of Chinese Academy of Sciences. Cancer cell lines were maintained in RPMI 1640 (HyClone, Logan city, USA) supplemented with 10% FBS. All the cell lines were in a 5% CO2 humidified atmosphere at 37°C. For siRNA transfection, cells were seeded out in six-well plates at a density of 2×10^5 cells/well, 24 h before transfection, siRNAs targeting non-overlapping parts of the mRNA sequence were used for flotillin2. For the depletion of flotillin2, a pool of two different siRNA with the sequences targeting construct GAGGUUGUGCAGCGCAUU and GGAUGAAGCUCAGCGGACA [15], the cells were seeded out without antibiotics, grown for 24 h and transfected by using Lipofectamine transfection reagent (Invitrogen) according to the manufacturer’s procedure. After 4 h of transfection, the medium was changed to complete growth medium containing serum and antibiotics, and the cells were grown for 3 days before experiments were started.

Immunofluorescence, Western blot and qRT-PCR

Cells were washed twice with cold PBS and lysed on ice in RIPA buffer with protease inhibitors and quantified by BCA method. 50 μg Protein lysates were resolved on 6% SDSPolyacrylamide gel, electrotransferred to polyvinylidene fluoride membranes (Millipore, Bedford, MA) and blocked in 5% nonfat dry milk in Tris-buffered saline (pH = 7.5). Membranes were immunoblotted overnight at 4°C with anti-flotillin2/erbB2 polyclonal antibodies as IHC described above, respectively, then followed by their respective secondary antibodies. Signals were detected by enhanced chemiluminescence (Pierce, Rockford, IL). For Immunofluorescence, the binding of primary antibody was visualized by
TRITC/FITC-conjugated goat anti-mouse IgG antibody, and the slides were then examined by a confocal laser scanning microscope.

PCR amplifications for quantification of flotillin2, erbB2 and GAPDH mRNA in cells were done in a LightCycler system (Roche Applied Science) using the LightCycler FastStart DNA Master SYBR Green I kit (Roche Diagnostics). In brief, a master mixture was prepared on ice, containing 1 μl of complementary DNA, 2 μl of LC DNA Master SYBR Green I mix, 50 ng of primers, and 4 mM MgCl2. The amplification conditions for 40 cycles consisted of denaturation at 95°C for 10 s, annealing at 65°C for 10 s, and extension at 72°C for 10 s. The products were then subjected to a temperature gradient from 68°C to 95°C at 0.1°C/s, with continuous fluorescence monitoring to produce melting curves of the products. The expression levels were normalized to erbB2 mRNA expression.

Table 2. Correlation of Flotillin2 and erbB2 expression with clinicopathologic parameters in gastric cancer.

| Variables           | Cases | Flotillin2 | P value | erbB2 | P value |
|---------------------|-------|------------|---------|-------|---------|
|                     |       | −          | +       | −     | +       |
| Gender              |       |            |         |       |         |
| male                | 205   | 113        | 92      | 68    | 9       |
| Female              | 77    | 40         | 37      | 155   | 50      |
| Age(years) <65      | 182   | 98         | 84      | 142   | 40      |
| Age(years) >65      | 100   | 55         | 45      | 81    | 19      |
| Size                |       |            |         |       |         |
| ≤4 cm               | 135   | 85         | 50      | 113   | 22      |
| >4 cm               | 147   | 68         | 79      | 110   | 37      |
| Location            |       |            |         |       |         |
| Lower               | 217   | 118        | 99      | 29    | 10      |
| Middle              | 21    | 12         | 9       | 15    | 6       |
| Upper               | 39    | 22         | 17      | 179   | 38      |
| Entire              | 5     | 1          | 4       | 0     | 5       |
| Macroscopic Type    |       |            |         |       |         |
| Early stage         | 31    | 24         | 7       | 29    | 2       |
| Bormann I           | 4     | 3          | 1       | 3     | 1       |
| Bormann II          | 20    | 12         | 8       | 19    | 1       |
| Bormann III         | 199   | 104        | 95      | 149   | 50      |
| Bormann IV          | 28    | 10         | 18      | 23    | 5       |
| Histologic type     |       |            |         |       |         |
| Differentiated      | 124   | 86         | 38      | 111   | 13      |
| Undifferentiated    | 158   | 67         | 91      | 112   | 46      |
| Lauren grade        |       |            |         |       |         |
| Intestinal          | 137   | 91         | 46      | 119   | 18      |
| Diffuse             | 145   | 62         | 83      | 104   | 41      |
| T Stage             |       |            |         |       |         |
| T1                  | 31    | 18         | 13      | 26    | 5       |
| T2                  | 50    | 29         | 21      | 29    | 6       |
| T3                  | 181   | 99         | 82      | 137   | 44      |
| T4                  | 20    | 7          | 13      | 16    | 4       |
| N Stage             |       |            |         |       |         |
| N0                  | 96    | 54         | 42      | 79    | 17      |
| N1                  | 45    | 33         | 15      | 39    | 9       |
| N2                  | 53    | 31         | 22      | 34    | 15      |
| N3                  | 88    | 38         | 50      | 71    | 17      |
| Lymphovascular invasion |     |            |         |       |         |
| Negative            | 207   | 120        | 87      | 57    | 43      |
| Positive            | 65    | 29         | 36      | 166   | 16      |

P values are based on a X2 test. *Significant difference doi:10.1371/journal.pone.0062365.t002
Statistical analysis

The χ² test or Fisher’s exact test for proportion was used, as appropriate, to analyze the relationship between flotillin2 and erbB2 expression and clinicopathological variables. The survival rates were calculated by the Kaplan–Meier method and the differences between the survival curves were examined by the log-rank test. Univariate Cox proportional hazards regressions were applied to estimate the individual hazard ratio (HR). The significant variables in the univariate analyses (P < 0.05) were then put into the multivariate analysis. The HR with 95% confidence interval (CI) was measured to estimate the hazard risk of individual factors. P < 0.05 was considered to be statistically significant. Analyses were performed using the SPSS statistical software program version 19.0 (SPSS Inc., Chicago, IL).

Results

Expressions of flotillin2 and erbB2 in gastric cancer

Stained sections of tissue microarrays (TMA) of 282 tissue cores were graded for their cytoplasmatic immunohistochemical staining intensity against flotillin2 and erbB2 protein. The 282 readable samples included 282 gastric carcinoma, 181 peri-carcinoma and 101 samples of normal gastric epithelium tissue. Tumor cells showed typical diffuse membrane staining of flotillin2 can be found in gastric carcinoma (Figure 1a) with the similar location of erbB2 (Figure 1b), in non-neoplastic gastric mucosa, flotillin2 and erbB2 were both not expressed. Positive staining of flotillin2 was shown in 129 (45.7%) of 282 specimens, erbB2 was 59 (20.9%). Amplification of erbB2 gene was determined by dual-colour FISH of xenografts in nude mice. ErbB2 gene amplification in a cluster pattern (red) was observed in MGC-803, BGC-823 and SGC-7901 cells, erbB2 overexpression only in human SGC-7901 gastric cancer cell (Figure 2a-c).

Association between the expressions of flotillin2 with erbB2

We analyzed the cellular localization of erbB2 and flotillins in SGC-7901 gastric cancer cell. We could show by confocal microscopy that flotillin2 partially co-localize with erbB2 at the plasma membrane (Figure 1a-c). Our data shows that the expression of flotillin2 do has a significant correlation with that of erbB2 (p < 0.001) in the immunohistochemical tissue array analysis (Table 1). In addition, interaction between flotillins and erbB2 could be demonstrated by immunoblot (Figure 2d) and quality RT-PCR experiments (Figure 2e), knocking down of endogenous flotillin2 resulted in pulling down of erbB2. We next analysed the impact of flotillins on the internalization and subsequent degradation of erbB2. As described below, erbB2 and her2 also have many relationships of clinicopathological factors in common.

Association between flotillin2 and clinicopathological factors

In this study, 282 gastric cancer patients with sufficient primary tumors materials and follow-up time were available, whose tissues were collected over the last 6 years. Table 2 gave the descriptive statistics for parameters measured for these patients. The median duration of the follow-up was 54 months (range 9–78 months). The 5-year overall survival (OS) rate was 48.2%.

We found that the increased expression of flotillin2 and erbB2 was both significantly associated with histological type (p < 0.001, respectively), Lauren grade (p < 0.001, respectively) and Lymphovascular invasion (p = 0.059 and p < 0.001, Table 2). In addition,

**Table 3.** Univariate analysis of prognostic variables in overall survival (OS) for patients.

| Variables               | Cases | 5-year OS(%) | P value |
|-------------------------|-------|--------------|---------|
| Gender                  |       |              | 0.351   |
| Female                  | 205   | 42.9         |         |
| male                    | 77    | 50.2         |         |
| Age(years)              |       |              | 0.04*   |
| <65                     | 182   | 52.7         |         |
| >65                     | 100   | 40           |         |
| Size                    |       |              | 0.001*  |
| ≤4 cm                   | 135   | 60.7         |         |
| >4 cm                   | 147   | 36.7         |         |
| Location                |       |              | 0.951   |
| Lower                   | 217   | 50.7         |         |
| Middle                  | 21    | 42.9         |         |
| Upper                   | 39    | 43.6         |         |
| Entire                  | 5     | 36.5         |         |
| Macroscopic Type        |       |              | 0.001*  |
| Early stage             | 31    | 87.5         |         |
| Borrmann I              | 4     | 50           |         |
| Borrmann II             | 20    | 80           |         |
| Borrmann III            | 199   | 44.7         |         |
| Borrmann IV             | 28    | 10.7         |         |
| Histologic type         |       |              | 0.134   |
| Differentiated          | 124   | 53.2         |         |
| Undifferentiated        | 158   | 44.3         |         |
| Lauren grade            |       |              | 0.117   |
| Intestinal              | 137   | 55           |         |
| Diffuse                 | 145   | 43.1         |         |
| T Stage                 |       |              | <0.001* |
| T1                      | 31    | 78.6         |         |
| T2                      | 50    | 65.7         |         |
| T3                      | 181   | 40.2         |         |
| T4                      | 20    | 15           |         |
| N Stage                 |       |              | <0.001* |
| N0                      | 96    | 72.9         |         |
| N1                      | 45    | 54.2         |         |
| N2                      | 53    | 46.9         |         |
| N3                      | 88    | 19.3         |         |
| Lymphovascular invasion |       |              | 0.001*  |
| Negative                | 207   | 53.1         |         |
| Positive                | 65    | 32.3         |         |
| erbB2 Expression        |       |              | <0.001* |
| Negative                | 223   | 53.4         |         |
| Positive                | 59    | 28.8         |         |
| Flotillin2 Expression   |       |              | <0.001* |
| Absent                  | 153   | 68           |         |
| Present                 | 129   | 24.8         |         |

*Significant difference.
doi:10.1371/journal.pone.0062365.t003
flotillin2 was significantly correlated with tumor size (p = 0.006), T stage (p = 0.001) and lymph node metastasis (p = 0.033, Table 2). However, no significant correlation was observed between flotillin2 expression and other parameters including age, gender, location, macroscopic type and hepatic metastasis.

Expression of flotillin2 in relation to prognosis
Using Cox’s proportional hazards regression model, the univariate relationships between tumor characteristics and patients’ outcome were obtained (Table 3). Of the 282 patients analyzed, statistically significant differences in OS were seen, with a poor outcome for patients with higher staining of flotillin2 and erbB2. Other predictive factors that were found to be correlated with OS were age (P = 0.042), size (P = 0.001), macroscopic type (P = 0.001), pT (P < 0.001) and pN stage (P < 0.001) (Table 3). Using log-rank test, there were significant differences in OS between positive and negative patients of flotillin2 and erbB2 (P < 0.001, respectively) in all patients were shown in Figure 3.

Cox multivariate proportional-hazard regression model was then used to determine which factors were jointly predictive of OS. Variables which were thought to be significant in univariate analysis were included in the analysis. The significance, adjusted for other co-variates, was given in Table 4. Multivariate analysis of the joint effect of flotillin2 and erbB2 with other prognostic factors showed that pT (P < 0.001) and pN stage (P < 0.001) flotillin2 (HR = 1.485, 95% CI: 1.278–1.725, P < 0.001) was a better independently prognostic marker than erbB2 (HR = 1.375, 95%CI: 1.133–1.947 P = 0.004) for OS (Table 4).

Discussion
The assessment of biological prognostic factors is of clinical importance, especially for a disease with poor outcome such as gastric cancer. The present study confirmed the constitutive expression of flotillin2 in gastric cancer tissue specimens and cell lines, we also found that flotillin2 was an independent poor prognostic factor of overall survival of gastric cancer patients. In addition, the present study showed, for the first time, a positive relationship between the expressions of flotillin2 and HER2 in gastric cancer. In the previous study, Pust et al. (2012) found that breast cancer cell lines derived from distant metastasis showed a higher level of flotillin mRNA and protein expressions than those derived from primary gastric cancer. Thus, they explained the role of flotillin2 as a tissue- and stage-specific tumor modulator, where it acts as an inhibitor or promoter of tumor formation and progression depending on its protein interaction partners such as growth factor receptors or cell adhesion molecules [11]. Our results agree with this description because flotillin2 expression in the present study was positively correlated with HER2 expression, which was positively correlated with poor prognosis in gastric cancer.

Data from two recent publications indicate that flotillin has a functional role in receptor tyrosine kinase signaling, especially in the activation of MAP kinase signaling and the regulation of FGF signaling in HeLa cells [16,17]. In the SKBR3 breast cancer cells, the result that Akt phosphorylation is reduced upon depletion of flotillin-2, but not after flotillin-1 knockdown, agreed with our data. Thus, receptor tyrosine kinases or receptor tyrosine kinase-

| Variables | 5-year OS(%) | HR(95%CI) | P value |
|-----------|--------------|----------|---------|
| Age       | 1.334 (0.940–1.895) | 0.107 |
| Size      | 1.078 (0.747–1.556) | 0.687 |
| Macroscopic Type | 1.434 (1.033–1.990) | 0.031 |
| T Stage   | 1.933 (1.344–2.781) | < 0.001* |
| N Stage   | 1.397 (1.188–1.642) | < 0.001* |
| Lymphovascular invasion | 1.055 (0.719–1.548) | 0.783 |
| erbB2     | 1.375 (1.133–1.947) | 0.004* |
| Flotillin2 | 1.485 (1.278–1.725) | < 0.001* |

HR hazard radio, CI confidence interval, *Significant difference. doi:10.1371/journal.pone.0062365.t004
mediated signaling pathways might be regulated by flotillins in different ways and/or in a cell type-specific manner, it is possible that the different signaling pathways triggered by erbB2 are regulated by either flotillin2. Nevertheless, the reduced erbB2 levels triggered by flotillin2 knockdown support our hypothesis of a flotillin2-mediated stabilization of erbB2.

Erbb2 is known to be associated with poor prognosis in gastric cancer, flotillins have been described to be associated with tumor genesis. We demonstrated that flotillin2 co-localizes with erbB2 at the plasma membrane and plays a functional role on the regulation of erbB2 in gastric cancer. High expression of flotillin2 is associated with poor prognosis and reduced survival time, and it emerges as a potential predictor of relapse in gastric cancer. It has been reported that oestrogen receptors were involved in gastric carcinogenesis and flotillin2 interacts with the receptors [18,19], indicating a significant impact of flotillin2 function on gastric cancer development. On the other hand, based on our tissue microarray studies, flotillin2 overexpression was highly associated with increased cell migration and malignant transformation leading to lymph node involvement and increased invasiveness. In our study, elevated flotillin2 and HER2 both showed a significant correlation with histologic type \((P<0.001\) both), Lauren grade \((P<0.001\) both), whereas flotillin2 also get a high relevance with T stage \((P=0.033)\) and lymph node metastasis \((P=0.033)\). This strong correlation suggests that flotillin2 can be used as a biomarker to identify subsets of patients with gastric cancer with a more aggressive phenotype. The multivariate analysis demonstrated flotillin2 serves as a better prognostic marker to predict the risk of metastasis and recurrence \((HR=1.405, 95\% CI: 1.270-1.725)\) than Her2 \((HR=1.375, 95\% CI: 1.133-1.947)\) for OS. We propose that flotillin2 over-expression may contribute to increased proliferation and the development of gastric cancers.

In conclusion, this is the first demonstration of a positive correlation between flotillin2 and erbB2 levels in cultured gastric cancer cells as well as in tissues. Moreover, flotillin2 expression level correlates with poor prognosis in gastric cancer, indicating that flotillin2 might be a prognostic biomarker for gastric cancer. It has been found that erbB2-overexpressing tumors are more likely to be resistant to treatment with an antibody-based (trastuzumab/Herceptin) therapy, which has become the clinical first-line treatment in patients with erbB2-overexpressing metastatic gastric cancer [20,21]. However, even in combination with other chemotherapeutical medications, more than 20% of patients with erbB2-overexpression show no response to the treatment. Thus, by targeting flotillin2 expression, new strategies in cancer treatment can be developed.

**Author Contributions**

Conceived and designed the experiments: ZZ. Performed the experiments: ZZ. Analyzed the data: XS ZW. Contributed reagents/materials/analysis tools: JW. Wrote the paper: ZZ.

**References**

1. Solis GP, Hoegg M, Munderloh C, Schrock Y, Malaga-Trillo E, et al. (2007) Regg-e/flotillin proteins are organized into stable tetramers in membrane microdomains. Biochem J 403: 313–322.
2. Zhao F, Zhang J, Liu YS, Li L, He YL (2011) Research advances on flotillins. ViroJ 8: 479.
3. Hazarika P, McCarty MF, Prieto VG, George S, Balsu D, et al. (2004) Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res 64: 7361–7369.
4. Doherty SD, Prieto VG, George S, Hazarika P, Dovic M (2006) High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma. Melanoma Res 16: 461–463.
5. Sasaki Y, Oshima Y, Koyama R, Maruyama R, Akashi H, et al. (2008) Identification of flotillin-2, a major protein on lipid rafts, as a novel target of p53 family members. Mol Cancer Res 6: 395–406.
6. Berger T, Ueda T, Arpaia E, Chios, II, Shirdel EA, et al. (2012) Flotillin-2 deficiency leads to reduced lung metastases in a mouse breast cancer model. Oncogene.
7. Jones RB, Gordin A, Krall JA, MacBeath G (2006) A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 443: 168–174.
8. Terasima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, et al. (2012) Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 18: 5992–6000.
9. Heskamp S, Laverman P, Rosak D, Boschetti F, van der Graaf WT, et al. (2012) Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nucl Med 53: 146–153.
10. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.
11. Pust S, Klokk TH, Muus N, Jensdahl M, Ribeberg B, et al. (2012) Flotillins as regulators of ErbB2 levels in breast cancer. Oncogene.

12. Kuenen J, Bobendorf L, Kallioniemä A, Barlund M, Schraimp P, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844–847.
13. Zhu Z, Zhao L, He A, Huang B, Karlsson A, et al. (2010) Retrovirus-mediated Drosophila melanogaster multidubstrite deoxynucleoside kinase gene therapy of gastric cancer cells in vitro and in vivo. Anticancer Res 30: 2641–2649.
14. Zhu Z, Mao L, Zhao L, Sun Z, Wang Z, et al. (2011) Synergistic therapeutic effect in gastric cancer cells produced by oncolytic adenovirus encoding Drosophila melanogaster deoxynucleoside-kinase kinase. Cancer Biol Ther 11: 874–880.
15. Punt S, Dyve AB, Torgersen ML, van Deurs B, Sandvig K (2010) Interplay between toxin transport and flotillin localization. PLoS One 5: e8840.
16. Amadelli M, Meister M, Banning A, Tomasovic A, Moor J, et al. (2012) Flotillin-1/reggie-2 protein plays dual role in activation of receptor-tyrosine kinase/mitogen-activated protein kinase signaling. J Biol Chem 287: 7265–7278.
17. Tomasovic A, Traub S, Tidkanen R (2012) Molecular networks in FGF signaling: Flotillin-1 and cl-associated protein compete for the binding to fibroblast growth factor receptor substrate 2. PLoS One 7: e29739.
18. Nakano N, Kikuchi F, Takato N, Azuma K, Taki S, et al. (2002) Expression of estrogen receptor-alpha and -beta mRNAs in human gastric cancer. Cancer Lett 176: 129–135.
19. Panyadecsa C, Dassen H, Klop J, Dunselaar K, Kamps R, et al. (2005) Oestrogen-modulated gene expression in the human endometrium. Cell Mol Life Sci 62: 239–250.
20. Uintch M, Fasching PA, Koutczy GE, Hasmuller S, Lebeau A, et al. (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29: 3351–3357.
21. Verma S, Miles D, Giannit K, Kups I, Welslau M, et al. (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367: 1783–1791.